Bristol-Myers Squibb Company’s YERVOY® (ipilimumab) Awarded Prestigious Prix Galien USA Prize for Best Biotechnology Product

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that YERVOY® (ipilimumab), a novel immunotherapy and the first medicine approved for unresectable or metastatic melanoma in more than a decade, received the Prix Galien USA 2012 Award for Best Biotechnology Product. The award, which is selected by a preeminent scientific committee that includes several Nobel Laureates, recognizes the technical, scientific and clinical research skills and achievements necessary to develop innovative medicines and devices and is considered the most prestigious prize in biopharmaceutical research and development.